Iradimed: A Most Agreeable Pretense

In the final quarter of 2025, Iradimed amassed $22.7 million in revenue – a seventeen percent improvement over the previous year. Their non-GAAP net income, a rather fanciful accounting measure, ascended by twenty-three percent to $0.54 per share. They surpassed the analysts’ expectations by a mere $0.06. A triumph, no doubt, but one built upon the shifting sands of expectation. After all, to consistently meet expectations is merely to avoid failure, not to achieve brilliance.







